Shares of AbbVie Inc. (NYSE:ABBV) have been assigned an average rating of “Buy” from the fifteen research firms that are covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $78.39.

Several equities research analysts have issued reports on ABBV shares. BMO Capital Markets reissued a “market perform” rating and set a $66.00 target price on shares of AbbVie in a research note on Wednesday, May 17th. Piper Jaffray Companies reissued a “buy” rating and set a $85.00 target price on shares of AbbVie in a research note on Thursday, August 3rd. Jefferies Group LLC reissued a “buy” rating and set a $94.00 target price on shares of AbbVie in a research note on Friday. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $100.00 target price (up previously from $85.00) on shares of AbbVie in a research note on Friday. Finally, Evercore ISI started coverage on AbbVie in a research note on Wednesday, August 16th. They set an “outperform” rating and a $95.00 target price for the company.

In related news, Chairman Richard A. Gonzalez sold 193,131 shares of the business’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $71.00, for a total value of $13,712,301.00. Following the transaction, the chairman now owns 469,623 shares in the company, valued at approximately $33,343,233. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Carlos Alban sold 45,800 shares of the business’s stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $70.00, for a total value of $3,206,000.00. Following the completion of the transaction, the executive vice president now owns 160,545 shares in the company, valued at approximately $11,238,150. The disclosure for this sale can be found here. Insiders have sold a total of 490,491 shares of company stock valued at $34,684,639 over the last ninety days. 0.23% of the stock is owned by company insiders.

A number of hedge funds have recently modified their holdings of ABBV. Capital Research Global Investors increased its position in AbbVie by 1.2% during the 2nd quarter. Capital Research Global Investors now owns 178,274,835 shares of the company’s stock worth $12,926,708,000 after purchasing an additional 2,130,919 shares during the period. Vanguard Group Inc. increased its position in AbbVie by 3.3% during the 2nd quarter. Vanguard Group Inc. now owns 115,920,673 shares of the company’s stock worth $8,405,409,000 after purchasing an additional 3,706,941 shares during the period. BlackRock Inc. increased its position in AbbVie by 2.0% during the 2nd quarter. BlackRock Inc. now owns 94,074,962 shares of the company’s stock worth $6,821,375,000 after purchasing an additional 1,864,418 shares during the period. State Street Corp increased its position in AbbVie by 2.4% during the 1st quarter. State Street Corp now owns 72,969,530 shares of the company’s stock worth $4,754,696,000 after purchasing an additional 1,696,042 shares during the period. Finally, Orbis Allan Gray Ltd increased its position in AbbVie by 35.7% during the 2nd quarter. Orbis Allan Gray Ltd now owns 12,704,919 shares of the company’s stock worth $921,233,000 after purchasing an additional 3,340,038 shares during the period. Hedge funds and other institutional investors own 68.29% of the company’s stock.

AbbVie (NYSE ABBV) traded up 4.35% during trading on Friday, hitting $85.34. The stock had a trading volume of 14,809,087 shares. The company’s 50 day moving average is $72.74 and its 200-day moving average is $68.51. The company has a market cap of $136.04 billion, a PE ratio of 20.99 and a beta of 1.48. AbbVie has a 12 month low of $55.06 and a 12 month high of $86.09.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 28th. The company reported $1.42 EPS for the quarter, topping the Zacks’ consensus estimate of $1.40 by $0.02. AbbVie had a return on equity of 150.27% and a net margin of 24.77%. The firm had revenue of $6.94 billion for the quarter, compared to the consensus estimate of $6.93 billion. During the same quarter last year, the business posted $1.26 earnings per share. The firm’s revenue was up 7.6% compared to the same quarter last year. On average, equities research analysts predict that AbbVie will post $5.52 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 15th. Shareholders of record on Friday, July 14th were issued a dividend of $0.64 per share. This represents a $2.56 dividend on an annualized basis and a yield of 3.00%. The ex-dividend date was Wednesday, July 12th. AbbVie’s dividend payout ratio (DPR) is 62.90%.

WARNING: “AbbVie Inc. (ABBV) Receives Consensus Recommendation of “Buy” from Analysts” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/09/09/abbvie-inc-abbv-receives-consensus-recommendation-of-buy-from-analysts-2.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.